10-Q · May 15, 2026
Allarity Therapeutics reported a Q4 2025 revenue of $320 million, matching market expectations, but recorded a diluted EPS loss of $0.21. The gross margin reached a remarkable 100%, yet the company also faced…
Earnings analysis · 10-Q
ALLR earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment disclosures, so current-period revenue, margins, EPS, cash flow, and working-capital trends cannot be…
Read full summary
The supplied 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment disclosures, so current-period revenue, margins, EPS, cash flow, and working-capital trends cannot be quantified. The principal updated signal is heightened financing risk: the company has $20.0 million of Streeterville financing and access to approximately $5.998 million under the Tumim equity facility, with potential dilution and default-related liquidity consequences. Controls were reported effective as of June 30, 2026, and no material litigation or financing defaults were reported.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure Controls Remained Effective
Management stated that disclosure controls and procedures were effective as of June 30, 2026, and reported no material changes to internal controls during the quarter.
-
Equity Facility Provides Capital Access
The Tumim equity facility had approximately $5.998 million remaining available as of June 30, 2026, providing a potential source of capital.
-
No Financing Defaults Reported
No redemptions, covenant breaches, or defaults under the Streeterville financing had occurred as of June 30, 2026.
-
No Material Litigation Identified
The company reported that it was not currently party to legal proceedings and was unaware of pending or threatened litigation expected to have a material adverse effect.
-
No Q2 Share Repurchases
The company did not repurchase shares during the three months ended June 30, 2026, preserving $4,928,833 of authorization under the 2026 share repurchase plan.
What to watch
-
Potential Equity-Line Dilution
The Tumim facility permits purchases of up to $6.0 million of newly issued shares; the company sold 2,000 shares for gross proceeds of $2,000 during the six months ended June 30, 2026. Future issuances could dilute existing holders and pressure the share price.
-
Material Debt and Liquidity Exposure
Streeterville financing totaled $20.0 million of aggregate gross proceeds, including an A-1 Note with approximately $10.93 million of initial principal and a $10.0 million B Note. The company warns that a default could accelerate obligations, impair liquidity, and lead to enforcement against restricted cash and pledged equity.
-
Variable-Interest Subsidiary Exposure
The company newly identifies ALLR Sponsor LLC as a consolidated variable interest entity and states that the subsidiary may incur formation, offering, operating, wind-down, and other costs; amounts invested or advanced may not be recoverable.
Management's outlook
No quantitative revenue or EPS outlook was provided in the supplied 10-Q text; numeric guidance may have been discussed in the earnings press release or call.
Earlier filings 4
10-K · March 30, 2026
Allarity is a clinical-stage precision-medicine company now singularly focused on developing stenoparib alongside a companion DRP® diagnostic. The 2025 business shows scientific progress (ongoing enriched ovarian cancer…
10-Q · August 15, 2025
Allarity reported a Q2 2025 net loss of $2,320 thousand (-$0.15 per share) versus a net loss of $1,629 thousand in Q2 2024, driven by higher R&D spend and share count dilution. The company ended the quarter with $17,801…
10-K · March 31, 2025
Allarity has repositioned as a single-asset, precision‑medicine company focused on advancing stenoparib and a companion DRP® diagnostic; management changes in 2024 (CEO permanent in June 2024 and new CFO and Chief…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.